Allergy & Immunology

The BTCRC LUN 16-081 trial is the first to evaluate a shorter, six-month course of consolidation immunotherapy using nivolumab alone or in combination with ipilimumab.

The study found that patients receiving the AR-PRISE intervention experienced significant improvements in symptom control, particularly over the longer term.

The study also highlighted the diagnostic challenges posed by unreliable histories and overlapping symptoms from infection-related exanthems.

Peanut oral immunotherapy (POIT), which involves gradually increasing exposure to peanut protein, has shown promise, successfully desensitising 50–70% of patients.

A recent landmark study is the first randomised, controlled trial to show clinical benefits of an allergy app for SAR sufferers.

In a new study, researchers identified a specific immune cell type, CD4+ T follicular helper (Tfh) cells producing IL-21 and IFN-γ, as a key driver of ICI-T1DM.

Discover a study linking everyday plastic chemicals to increased risks of asthma, wheezing, and allergies in young children.

Traditionally, FA management has focused on avoidance or reducing allergenicity by altering the protein structure of allergens through heat, pressure or other treatments.